Tumor suppressor genes have an essential function in controlling cell growth, DNA repair, and apoptosis, serving as natural brakes to cancer formation. This session "Tumor Suppressors" addresses their mechanisms, clinical relevance, and future therapeutic prospects in oncology.".
When tumor suppressor genes become inactivated or lost due to mutations, deletions, or epigenetic modifications, cells can proliferate in an uncontrollable manner, avoid apoptosis, and amass more mutations, giving rise to cancer development. The important tumor suppressors TP53, RB1, and PTEN are commonly mutated in a number of cancer types and thus serve as vital biomarkers for diagnosis, prognosis, and treatment choice.
This session discusses ways to restore tumor suppressor function or target pathways disrupted by their loss. New treatment options include gene therapy, small molecules, and synthetic lethality strategies aimed at taking advantage of vulnerabilities created by the inactivation of tumor suppressors. Molecular profiling and biomarker analysis are critical for determining which patients are likely to benefit from these treatments.
Participants will learn about the biology, clinical relevance, and therapeutic potential of tumor suppressors. This lecture highlights the potential for understanding and targeting tumor suppressor pathways to lead to novel, targeted cancer therapies, enhance patient care, and move the precision oncology field forward.
Welcome to the Cancer and Oncology Conference 2026, where global researchers, clinicians, and academics meet to share advances in cancer biology, precision medicine, diagnostics, therapies, and global solutions for patient care.
